跳至主要内容
临床试验/NCT01961947
NCT01961947已完成3 期

Phase 3 Study of ASP7374 -Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Adults ≥20 and <65 Years of Age-

UMN Pharma Inc.2 个研究点 分布在 1 个国家目标入组 900 人开始时间: 2013年10月最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
900
试验地点
2
主要终点
seroconversion rate of hemagglutination inhibition (HI) antibody titer

研究概览

简要总结

The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (TIV) in adults ≥20 and <65 years.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy or medically stable, as judged on the basis of history and concurrent diseases.
  • Subject understands procedure of the protocol and is willing to comply with the protocol.
  • Written informed consent has been obtained.

排除标准

  • Scheduled to receive another vaccine during the study.
  • Received influenza HA vaccine within 180 days prior to screening.
  • Received or scheduled to receive a live vaccine within 28 days prior to vaccination with the study vaccine, and received or scheduled to receive an inactivated vaccine or a toxoid within 7 days prior to vaccination with the study vaccine.
  • Diagnosis of immune deficit in the past, has a family member (within the third degree of kinship) with a diagnosis of congenital immunodeficiency syndrome.
  • Received one of the following medications or treatment prior to vaccination with the study vaccine.
  • Received one of the following medications or treatment prior to vaccination with the study vaccine: Interferon formulation, Drugs which affect the immune system, corticosteroids, G-CSF, M-CSF, Human immunoglobulin products, Blood products, Blood transfusion
  • History of anaphylactic shock or an allergic reaction such as generalized eruption due to food (including chicken, poultry, foodstuffs derived from chicken, et al.) or drug (including vaccines) allergies, fever ≥39.0°C within 2 days after the previous vaccination (influenza vaccine and others)
  • History of seizures, except for febrile seizures in childhood

研究组 & 干预措施

TIV group

Active Comparator

干预措施: approved egg-derived TIV (Biological)

ASP7374 group

Experimental

干预措施: ASP7374 (Biological)

结局指标

主要结局

seroconversion rate of hemagglutination inhibition (HI) antibody titer

时间窗: Day 29

evaluated for A/H1N1, A/H3N2, and B

geometric mean titer (GMT) of HI antibody titer

时间窗: Day 29

evaluated for A/H1N1, A/H3N2, and B

次要结局

  • seroprotection rate of HI antibody titer(Day 29)
  • GMT of neutralizing antibody titer(Day 29)
  • GMT ratio of HI antibody titer (Day 29/Day 1)(Day1 and Day 29)
  • seroconversion rate of neutralizing antibody titer(Day 29)
  • seroprotection of neutralizing antibody titer(Day 29)
  • GMT ratio of neutralizing antibody titer (Day 29/Day 1)(Day 1 and Day 29)
  • Local and systemic reactions associated with the vaccination(Day 1 through Day 8)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验